<DOC>
	<DOC>NCT00969553</DOC>
	<brief_summary>The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 in Asian cancer patients, and to provide safety data in terms of drug-related adverse events.</brief_summary>
	<brief_title>Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers</brief_title>
	<detailed_description />
	<criteria>Inclusion criteria: 1. Patients with histologically or cytologically confirmed diagnosis of advanced solid cancer 2. Age 18 years or older 3. Written informed consent 4. Eastern Cooperative Oncology Group (ECOG) performance score 2 or less Exclusion criteria: 1. Serious illness or concomitant nononcological disease. 2. Pregnancy or breast feeding 3. Active infectious disease 4. Absolute neutrophil count less than 1,500/cubic millimeter 5. Platelet count less than 100,000/cubic millimeter 6. Bilirubin greater than 1.5 mg/dL (&gt; 26 Âµmol/L, SI unit equivalent) 7. Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal 8. Serum creatinine greater than 1.5x ULN.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>